(Total Views: 644)
Posted On: 05/03/2025 3:28:15 PM
Post# of 154723
FDA Grants Cytodyn Fast Track Designation for Leronlimab (Pro140) in Metastatic Triple-Negative Breast Cancer, an unmet medical need __VANCOUVER, Washington, May 07. 2019...
"This is an important acknowledgement of the potentially paradigm-shifting therapy option in metastatic triple-negative breast cancer," ___stated Dr. Richard Pestell, M.D., Vice Chairman and Chief Medical Officer of Cytodyn.
We thank the FDA for recognizing the potential of Leronlimab (PRO140) for mTNBC patients."
That was almost exactly 6 years ago.
My question is this; is that nomination grandfathered in???
"This is an important acknowledgement of the potentially paradigm-shifting therapy option in metastatic triple-negative breast cancer," ___stated Dr. Richard Pestell, M.D., Vice Chairman and Chief Medical Officer of Cytodyn.
We thank the FDA for recognizing the potential of Leronlimab (PRO140) for mTNBC patients."
That was almost exactly 6 years ago.
My question is this; is that nomination grandfathered in???
(3)
(0)
